La cadena de opciones muestra datos clave de las opciones de acciones de Esperion Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Esperion Therapeutics..

Esperion Therapeutics (NASDAQ:ESPR) Bolsa, Cadena de Opciones

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HOLDINS LTD by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

JMP Securities analyst Roy Buchanan reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

ESPR

JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) from Buy to Buy.

HC Wainwright & Co. Reiterates Buy on Esperion Therapeuticsto Buy

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
– New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty –

Esperion Secures $250M In Refinancing To Strengthen Balance Sheet And Extend Debt Maturity

Goldman Sachs analyst Paul Choi reinstates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Neutral and announces $4 price target.

Initiation

Goldman Sachs Reinstates Neutral on Esperion Therapeutics, Announces $4 Price Target

WIIM

Esperion Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $8.

CORRECTION: Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Overweight rating and announces Price Target of $8. -Analyst Firm Updated

CORRECTION: Cantor Fitzgerald Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $8 -Analyst Firm Updated

Wedbush analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Overweight rating and announces Price Target of $8.

Wedbush Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $8

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCYC

BRNS

CADL

CVKD

ISPC

LTRN

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $6 price target.

Needham Reiterates Buy on Esperion Therapeutics, Maintains $6 Price Target

Offerings

Esperion Enters Privately Negotiated Exchange And Subscription Agreements With Certain Holders Of 4.00% Convertible Senior Subordinated Notes Due 2025

Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales –
– Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years

Biotech

Contracts

General

Esperion Partners with Neopharm To Commercialize NEXLETOL, NEXLIZET In Israel; Terms Not Disclosed

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

HC Wainwright & Co. Maintains Buy on Esperion Therapeutics, Maintains $16 Price Target

Esperion Therapeutics shares are trading higher after the company announced it has filed a new drug submission to Health Canada for Nexletol and Nexlizet.

Health Care

Esperion Has Filed New Drug Submissions To Health Canada For Nexletol And Nexlizet, Once-daily, Accessible, Oral Non-statin Medications That Reduce Low-density Lipoprotein Cholesterol And Cardiovascular Risk.

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.

Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who Took Bempedoic Acid Were 36% Less Likely To Experience A Major Adverse Limb Event Compared To Placebo

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Micron (MU) reported upbeat Q1 e...

Micron sinks on guidance, TripAdvisor to buy Liberty TripAdvisor: Morning Buzz

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading... The biotech market is experiencing robust growth, fueled by demand for better treatment, personalized medicines, and an increasing number of orphan drug formulations. Further, cutting-edge technology, like AI and supportive government initiatives, are opening wider opportunities for the market.
Given the industry's shiny prospects, investors could consider watching fundamentally sound biotech stocks MannKind Corporation (<a href="https://stocknews.com/stock/MNKD/">MNKD</a>), Amicus Therapeutics, Inc. (<a href="https://stocknews.com/stock/FOLD/">FOLD</a>), and Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>).
Biotech is revolutionizing the face of the healthcare segment with the introduction of new therapies, vaccines, and processes targeting new and rare diseases and conditions. Supportive initiatives by the governments and the adoption of the latest technologies are further contributing to the advancements in the segment.
In this year alone, the U.S. Food and Drug Administration (FDA) has approved <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">46 new drugs</a> for conditions such as lung cancer, refractory acute leukemia, breast cancer, schizophrenia, and more. These breakthroughs will help in treating numerous patients and position the sector for even more growth.
Also, with the ongoing advancements in science and technology, <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html">more breakthrough innovations</a> are anticipated in the coming times. Amid this, a vast majority of global life sciences executives appear optimistic about the prospects of the market in 2025.
The global biotechnology market is projected to grow at a CAGR of 14%, resulting in a market volume of <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.88 trillion by 2030</a>. Currently, the market is driven by efforts towards modernization of regulatory framework, demand for personalized medicine, an increasing number of orphan drug formulations, and emerging innovative technologies.
Also, in 2024, <a href="https://www.pharmiweb.com/press-release/2024-04-15/generative-ai-in-biotech-market-to-skyrocket-to-usd-472-million-by-2032-marketresearchbiz#:~:text=Generative%20AI%20in%20Biotech%20utilizes,innovation%20and%20drug%20candidate%20identification.">artificial intelligence (AI)</a> continued to strengthen its position in the biotech industry, equipping the segment with rapid drug discovery, enhanced accuracy, customized drug design, and expanded data availability. Cutting-edge technology is accelerating the development process and helping design novel molecules.
Therefore, high-growth biotech stocks present promising opportunities for investors in the long term. In light of these encouraging trends, let's look at the fundamentals of the three high-growth <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, starting with number 3.
Stock #3: MannKind Corporation (<a href="https://stocknews.com/stock/MNKD/">MNKD</a>)
MNKD is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. It offers Afrezza and the V-Go wearable insulin delivery device.
On December 11, MNKD and Cipla Ltd. announced that India's Central Drugs Standard Control Organisation (CDSCO) approved its Afrezza (insulin human) Inhalation Powder in adults. The decision followed the existing approvals in the United States and Brazil. MNKD will supply Afrezza to Cipla, and Cipla will distribute Afrezza in India and undertake its marketing and sales activities.
On September 18, MNKD received clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to initiate the Phase 3 study (ICoN-1) of Clofazimine Inhalation Suspension for treating NTM lung disease. The approval will allow MMNKD to develop a potential therapy for those living with serious NTM lung infections and help them further.
For the third quarter that ended September 30, 2024, MNKD's total <a href="https://www.investopedia.com/terms/r/revenue.asp">revenues</a> rose 36.7% year-over-year to $70.08 million. The company's income from operations of $12.76 million indicates growth of 150.3% from the prior year's quarter. Its non-GAAP adjusted net income came in at $15.35 million and $0.06 per share, up 260.7% and 200% year-over-year, respectively.
Analysts expect MNKD's revenue for the fourth quarter (ending December 2024) to grow 28.1% year-over-year to $74.88 million, and its EPS is expected to increase 539.5% year-over-year to $0.03 for the same period. Moreover, the company has surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Over the past six months, the stock has surged 24.3% and 59.3% over the past year to close the last trading session at $5.94.
MNKD's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
MNKD has a B grade for Growth and Quality. It is ranked #28 out of 331 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
To check other POWR Ratings of MNKD for Value, Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/MNKD/">click here</a>.
Stock #2: Amicus Therapeutics, Inc. (<a href="https://stocknews.com/stock/FOLD/">FOLD</a>)
FOLD is a biotechnology company focused on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold and Pombiliti + Opfolda.
In terms of trailing-12-month gross profit margin, FOLD's 89.99% is 54.2% higher than the industry average of 58.37%. Similarly, the stock's trailing-12-month EBIT margin of 2.92% is 14.5% higher than the industry average of 2.55%. Further, its trailing-12-month asset turnover ratio of 0.64x is 52.9% higher than the industry average of 0.42x.
During the third quarter that ended September 30, 2024, FOLD's net product revenues rose 36.7% year-over-year to $141.52 million. The company's gross profit grew 37.1% from the year-ago value to $128.24 million. Also, the company's non-GAAP net income amounted to $30.79 million or $0.10 per common share for the quarter, respectively.
Analysts expect FOLD's revenue for the first quarter (ending March 2025) to increase 28.6% year-over-year to $142 million. For the fiscal year 2024, the company's revenue is expected to grow 31.7% year-over-year to $525.98 million. Also, the company topped the consensus revenue estimates in three of the trailing four quarters.
Shares of FOLD have plunged marginally over the past month to close the last trading session at $9.57.
FOLD's POWR Ratings reflect its robust outlook. FOLD has an A grade for Growth. It also has a B grade for Value. It is ranked #44 among 331 stocks within the Biotech industry.
To see the other ratings of FOLD for Quality, Sentiment, Momentum, and Stability, <a href="https://stocknews.com/stock/FOLD/">click here</a>.
Stock #1: Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR is a pharmaceutical company that emphasizes developing and commercializing medicines for treating patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets.
On December 12, ESPR entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Israel. Under the agreement, Esperion will receive upfront and near-term milestone payments and tiered royalties on sales of NEXLETOL/NEXLIZET in Israel.
During the third quarter that ended September 30, 2024, ESPR's total revenues increased 52% year-over-year to $51.63 million, of which its collaboration revenue came in at $20.53 million, up 49.6% from the prior year's quarter. In addition, the company's cash and cash equivalents were $144.72 million as of September 30, 2024, compared to $82.25 million as of December 31, 2023.
Street expects ESPR's revenue for the fourth quarter (ending December 2024) to increase 92.7% year-over-year to $62.14 million. Similarly, for the fiscal year 2024, the company's revenue is expected to grow 181.2% year-over-year to $327.16 million. Furthermore, ESPR has surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
ESPR's stock has gained 2.1% over the past month and 2.4% over the past year to close the last trading session at $2.16.
ESPR's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth, Value, and Quality. Within the same industry, ESPR is ranked #42 among the 331 stocks.
<a href="https://stocknews.com/stock/ESPR/">Click here</a> to access additional ratings of ESPR for Stability, Sentiment, and Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
FOLD shares were trading at $9.80 per share on Thursday afternoon, up $0.23 (+2.40%). Year-to-date, FOLD has declined -30.94%, versus a 25.17% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/fold-mnkd-espr-3-high-growth-biotech-stocks-to-watch/>3 High-Growth Biotech Stocks to Watch</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth Biotech Stocks to Watch

Healthcare innovators are gaining momentum as they address critical challenges in biotechnology, medical devices, and pharmaceuticals. Amid this backdrop, you might consider keeping an eye on three healthcare innovators, Zoetis (ZTS), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), which have robust upside potential. Read on… Healthcare innovation is at the forefront of investment trends as companies push boundaries in biotechnology, medical devices, and pharmaceuticals. These innovators are developing groundbreaking solutions to address chronic diseases, improve patient outcomes, and streamline medical processes.
Below, I have highlighted three healthcare innovators: Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), which are well-positioned for potential upside gain.
Biotechnology companies are leading the charge, leveraging gene editing and immunotherapy to combat diseases once considered incurable, with the focus being on innovation-driven growth. According to the American Society of Gene and Cell Therapy (ASGCT), <a href="https://www.labiotech.eu/more-news/biotech-2024-retrospective/">a total of 32 gene therapies and 34 RNA therapies have been approved</a> globally by the third quarter of 2024.
Moreover, innovation in healthcare is active across multiple sectors. With that being said, medical device manufacturers are also an area of focus as they introduce new technologies to improve diagnostics and surgical procedures. <a href="https://www.inpart.io/blog/17-top-healthcare-innovations-2023">From wearable health monitors to robotic surgery systems</a>, these innovations are driving demand and revenue.
The global healthcare services market is projected to reach <a href="https://www.verifiedmarketresearch.com/product/healthcare-services-market/">$22.57 trillion by 2031</a>, growing at a CAGR of 8.3%. With robust pipelines and strategic partnerships, healthcare companies are well-positioned to thrive in an evolving healthcare landscape.
Given these factors, let's delve deeper into the fundamentals of the above-mentioned stocks:
Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>)
ZTS is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health. 
On December 12, demonstrating its commitment to returning value to shareholders, the company declared a quarterly dividend of $0.50 per share, an increase of 16%, payable on March 4, 2025, to shareholders of record at the close of business on January 21, 2025.
ZTS pays an annual dividend of $2, which translates to a yield of 1.21% at the current share price. Its four-year average dividend yield is 0.73%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 20% over the past three years.
On September 26, ZTS and Danone SA together announced a joint business development plan to drive sustainable practices on dairy farms through the power of genetics for healthier cows. This strategic partnership aims to innovate the dairy industry's approach to breeding for sustainability with ZTS' genetic testing solutions.
During the third quarter that ended on September 30, 2024, ZTS' <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> increased 11% year-over-year to $2.39 billion. It posted a non-GAAP gross profit of $1.69 billion, indicating an 11.4% increase from the prior-year quarter. In addition, its non-GAAP net income and non-GAAP EPS amounted to $716 million and $1.58, reflecting increases of 13.8% and 16.2% year-over-year, respectively.
The consensus revenue estimate of $2.33 billion for the fiscal fourth quarter (ending December 2024) represents a 5.2% increase year-over-year. The consensus EPS estimate of $1.36 for the same quarter indicates a 9.4% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue estimates in each of the trailing four quarters.
ZTS' EBIT has grown at CAGRs of 6.8% and 9.8% over the past three and five years, respectively. Likewise, the company's diluted EPS has increased at a CAGR of 11.9% over the past three years.
ZTS shares have surged marginally intraday to close the last trading session at $164.70.
The 12-month median price target of $211 indicates <a href="https://www.tipranks.com/stocks/zts/forecast">a 28.1% upside potential</a> from the last closing price. The price targets range from a low of $180 to a high of $248.
ZTS' <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
ZTS has a B grade for Stability, Sentiment, and Quality. It is ranked #21 out of 149 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/ZTS/">Click here</a> to see the additional ratings for ZTS (Growth, Value, and Momentum).
Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Based in Tübingen, Germany, IMTX, a clinical-stage biopharmaceutical company, is focused on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities.
In the fiscal third quarter that ended on September 30, 2024, IMTX's revenue from collaboration agreements increased 753.2% year-over-year to €50.56 million ($52.54 million). As of September 30, 2024, IMTX's cash reached €189.19 million ($196.62 million), with total assets amounting to €577.23 million ($599.88 million) as of September 30, 2024.
Analysts expect IMTX's revenue for the fiscal year (ending December 2024) to grow 107.4% year-over-year to $121.56 million. 
Over the past three years, IMTX's revenue and total assets grew at CAGRs of 59.5% and 42.6%, respectively.
The stock has gained marginally intraday to close the last trading session at $7.10.
Based on Wall Street analysts offering 12-month price targets for IMTX in the last three months, <a href="https://www.tipranks.com/stocks/imtx/forecast">the average target price is $16.92</a>, indicating a 138.3% change from the last price.
IMTX's stance is apparent in its POWR Ratings. The stock has a B grade for Value and Sentiment. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #55. <a href="https://stocknews.com/stock/IMTX/">Click here</a> to see the additional IMTX ratings (Growth, Momentum, Stability, and Quality).
Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On December 12, ESPR announced that it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Israel.
In this agreement, ESPR will receive an upfront payment and near-term milestones along with tiered royalties. This agreement should also expand ESPR's global reach for cardiovascular and cardiometabolic diseases.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to prescribe it to primary and secondary prevention patients easily.
For the nine-month period that ended on September 30, 2024, ESPR's total revenues increased 213% year-over-year to $263.20 million. Its income from operation came in at $58.82 million compared to a year-ago net loss of $113.19 million. The company's cash and cash equivalents and total assets came in at $144.72 million and $314.11 million as of September 30, 2024.
Street expects ESPR's revenue for the fiscal fourth quarter (ending December 2024) to increase 92.7% year-over-year to $62.14 million. In addition, it surpassed the revenue estimates in three of the trailing four quarters, which is promising.
Moreover, ESPR's revenue has grown at CAGRs of 59.6% and 14.9% over the past three and five years, respectively. In addition, its total assets increased at 11.7% CAGR over the past three years.  
Over the past three months, the stock has surged 39.4%, closing the last trading session at $2.30.
Based on Wall Street analysts offering 12-month price targets for ESPR in the last three months, <a href="https://www.tipranks.com/stocks/espr/forecast">the average target price is $6.86</a>, indicating a 198.3% change from the last price, with a high forecast of $16 and a low forecast of $2.05.
ESPR's fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth, Value, and Quality. It is ranked #39 out of 335 stocks in the Biotech industry.
Beyond what is stated above, we've also rated ESPR for Momentum, Stability, and Sentiment. Get all ESPR's ratings <a href="https://stocknews.com/stock/ESPR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZTS shares were trading at $165.04 per share on Thursday afternoon, up $0.34 (+0.21%). Year-to-date, ZTS has declined -15.55%, versus a 28.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/zts-imtx-espr-3-healthcare-innovators-with-analyst-endorsed-upside/>3 Healthcare Innovators with Analyst-Endorsed Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Innovators with Analyst-Endorsed Upside

Small-cap healthcare stocks offer a unique opportunity for investors looking to capitalize on innovation and high growth. Thus, investors might consider keeping an eye on three small-cap healthcare stocks, Verve Therapeutics (VERV), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), that offer big upside potential. Read on… Small-cap healthcare companies are companies with a market capitalization of <a href="https://www.investopedia.com/terms/s/small-cap.asp">up to $2 billion</a>, which often go unnoticed, but they hold immense potential for investors seeking high-growth opportunities. These companies are typically at the forefront of innovation, focusing on niche markets or groundbreaking therapies.
Below, I have highlighted three small-cap healthcare stocks: Verve Therapeutics, Inc. (<a href="https://stocknews.com/stock/VERV/">VERV</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), offering significant upside potential.
The key driver of small-cap healthcare companies is their focus on specialized treatments. Many of these companies are involved in developing therapies for rare diseases or unmet medical needs, which often come with lucrative market exclusivity periods. The successful commercialization of even a single product can lead to exponential growth for these firms.
According to Deloitte's outlook, <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-us-health-care-executive-outlook.html">2025 might be a turnaround period for the healthcare sector</a> driven by innovation, resilience, and strategic growth. As global healthcare spending continues to rise, fueled by aging populations and increased focus on innovation, small-cap companies will likely see sustained demand for their specialized offerings.
The global healthcare market is projected to reach $44.760 trillion by 2032, <a href="https://www.globenewswire.com/news-release/2024/08/01/2923001/0/en/Healthcare-Market-Size-Worth-US-44-760-73-Billion-By-2032-Continuous-Advancements-in-Biotechnology-Pharmaceuticals-Propels-Growth-Research-by-SNS-Insider.html">exhibiting a CAGR of 9.1%</a>. This growth signifies increased investment and innovation, driving further advancements and improvements in patient care.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Verve Therapeutics, Inc. (<a href="https://stocknews.com/stock/VERV/">VERV</a>)
With a market cap of $508.83 million, VERV is a clinical-stage genetic medicines company that engages in developing gene-editing medicines for patients to treat cardiovascular diseases. The company's product portfolio consists of VERVE-101, VERVE-102, and ANGPTL3 programs.
VERV, for the third quarter (ended September 30, 2024), reported collaboration <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> of $6.87 million, indicating a 120.2% growth from the prior-year quarter. Its cash and cash equivalents and total assets came in at $158.71 million and $663.91 million as of September 30, 2024.
For the fiscal year (ended December 2024), Street expects VERV's revenue to grow by 99.4% year-over-year to $23.44 million.
VERV's total assets have grown at a CAGR of 17.4% over the past three years. Likewise, the company's tangible book value has increased at a CAGR of 9.7% over the past three years.
VERV shares have surged 32.9% over the past three months and 6% over the past six months to close the last trading session at $6.01.
The 12-month median price target of $25.67 indicates <a href="https://www.tipranks.com/stocks/verv/forecast">a 327.1% upside potential</a> from the last closing price. The price targets range from a low of $15 to a high of $35.
VERV's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 339 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #123. <a href="https://stocknews.com/stock/VERV/">Click here</a> to see the VERV ratings (Growth, Value, Momentum, Stability, Sentiment, and Quality).
Stock #2: Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Based in Tübingen, Germany, IMTX, a clinical-stage biopharmaceutical company, is focused on researching and developing potential T-cell redirecting immunotherapies for cancer treatment. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities. It has a market cap of $847.20 million.
In the fiscal third quarter that ended on September 30, 2024, IMTX's revenue from collaboration agreements increased 753.2% year-over-year to €50.56 million ($52.54 million). As of September 30, 2024, IMTX's cash reached €189.19 million ($196.62 million), with total assets amounting to €577.23 million ($599.88 million) as of September 30, 2024.
Analysts expect IMTX's revenue for the fiscal year (ending December 2024) to grow 106.9% year-over-year to $121.27 million. 
Over the past three years, IMTX's revenue and total assets grew at CAGRs of 59.5% and 42.6%, respectively.
The stock has declined marginally intraday to close the last trading session at $6.97.
Based on Wall Street analysts offering 12-month price targets for IMTX in the last three months, <a href="https://www.tipranks.com/stocks/imtx/forecast">the average target price is $16.58</a>, indicating a 137.9% change from the last price.
IMTX's POWR Ratings reflect this outlook. It has a B grade for Value and is ranked #58 out of 339 stocks in the same industry. To see the other ratings of IMTX for Growth, Value, Momentum, Stability, Sentiment, and Quality, <a href="https://stocknews.com/stock/IMTX/">click here</a>.
Stock #1: Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR is a pharmaceutical company that has a market cap of $427.57 million, and it develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On December 12, ESPR announced that it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Israel.
In this agreement, ESPR will receive an upfront payment, near-term milestones, and tiered royalties. This agreement should also expand ESPR's global reach for cardiovascular and cardiometabolic diseases.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to prescribe it to primary and secondary prevention patients easily.
For the nine-month period that ended on September 30, 2024, ESPR's total revenues increased 213% year-over-year to $263.20 million. Its income from operation came in at $58.82 million compared to a year-ago net loss of $113.19 million. The company's cash and cash equivalents and total assets came in at $144.72 million and $314.11 million as of September 30, 2024.
Street expects ESPR's revenue for the fiscal fourth quarter (ended December 2024) to increase 92.7% year-over-year to $62.14 million. In addition, it surpassed the revenue estimates in three of the trailing four quarters, which is promising.
Moreover, ESPR's revenue has grown at CAGRs of 59.6% and 14.9% over the past three and five years, respectively. In addition, its total assets increased at 11.7% CAGR over the past three years. 
Over the past three months, the stock has surged 4.8%, closing the last trading session at $2.17.
Based on Wall Street analysts offering 12-month price targets for ESPR in the last three months, <a href="https://www.tipranks.com/stocks/espr/forecast">the average target price is $6.86</a>, indicating a 216.1% change from the last price, with a high forecast of $16 and a low forecast of $2.05.
ESPR's fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth, Value, and Quality. It is ranked #42 in the Biotech industry.
Beyond what is stated above, we've also rated ESPR for Momentum, Stability, and Sentiment. Get all ESPR's ratings <a href="https://stocknews.com/stock/ESPR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
IMTX shares were trading at $6.97 per share on Thursday afternoon, down $0.07 (-0.99%). Year-to-date, IMTX has declined -1.97%, versus a 0.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/imtx-verv-espr-3-small-cap-healthcare-stocks-with-big-upside-potential/>3 Small-Cap Healthcare Stocks With Big Upside Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Healthcare Stocks With Big Upside Potential

JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00. Jason Butle...

Buy Rating for Esperion Based on Strong Clinical Data and Market Adoption of NEXLETOL and NEXLIZET

Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. ...

Promising Potential of Esperion's Non-Statin Drugs in Cardiovascular Disease Management

AAPL

AGCO

AMZN

CTAS

FOLD

IMTX

KULR

LTRPA

MLKN

MNKD

OKLO

RIVN

RZLV

TCEHY

TCTZF

TRIP

TSLA

VERV

VKTX

Press Releases

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

Comments

Esperion Therapeutics

Esperion Therapeutics (ESPR) Opciones

Esperion Therapeutics (NASDAQ:ESPR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL